Cogent Biosciences(COGT) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Cogent Biosciences Reports First Quarter 2025 Financial Results Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in cash, suf icient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo., May 6, 2025 – Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on develo ...